Drug Profile
Lestaurtinib - Teva Pharmaceuticals
Alternative Names: CEP-701; KT 5555; SPM 924Latest Information Update: 09 Apr 2021
Price :
$50
*
At a glance
- Originator Kyowa Hakko
- Developer Cephalon; Children's Oncology Group; Icahn School of Medicine at Mount Sinai; Kyowa Hakko; National Cancer Institute (USA); Teva Pharmaceutical Industries
- Class Antineoplastics; Antipsoriatics; Antithrombotics; Carbazoles; Indoles; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Janus kinase-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Acute myeloid leukaemia; Multiple myeloma; Myelofibrosis; Pancreatic cancer; Plaque psoriasis; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Thrombocytosis
Most Recent Events
- 25 Jan 2018 Lestaurtinib is still in phase III trials for Acute lymphoblastic leukaemia (Combination therapy, In infants, Newly diagnosed) in USA, New Zealand, Canada and Australia (PO) (NCT00557193)
- 04 Sep 2015 Phase-II development for Acute myeloid leukaemia (Second-line therapy or greater, Combination therapy), Myelofibrosis, Polycythaemia vera and Thrombocytosis is ongoing in USA
- 04 Sep 2015 No recent reports on development identified - Phase-II for Acute myeloid leukaemia (Second-line therapy or greater) in Ukraine, Sweden, Spain, Australia, Canada, Germany, Israel, Italy, New Zealand, Poland, Romania and Russia (PO)